Journal of Neurology

, Volume 254, Issue 7, pp 827–837

Neutralising antibodies to interferon β in multiple sclerosis

Expert panel report
  • H.-P. Hartung
  • C. Polman
  • A. Bertolotto
  • F. Deisenhammer
  • G. Giovannoni
  • E. Havrdova
  • B. Hemmer
  • J. Hillert
  • L. Kappos
  • B. Kieseier
  • J. Killestein
  • C. Malcus
  • M. Comabella
  • A. Pachner
  • H. Schellekens
  • F. Sellebjerg
  • K. Selmaj
  • P. S. Sorensen
REVIEW

DOI: 10.1007/s00415-006-0486-3

Cite this article as:
Hartung, H., Polman, C., Bertolotto, A. et al. J Neurol (2007) 254: 827. doi:10.1007/s00415-006-0486-3

Abstract

Interferon beta (IFNβ) therapy for multiple sclerosis (MS) is associated with a potential for the development of neutralising antibodies (NAbs) that negatively affect therapy. Several factors influence the development of NAbs, such as lack of complete sequence homology with the endogenous IFNβ sequence, frequency of administration, level of dose and formulation of IFNβ. Taken together, the evidence that NAb status reduces clinical efficacy in MS patients is strong. Standardised assays for NAbs are lacking, and titres vary over time. NAb testing is a critical component of care for MS patients because it provides information on one of the most important factors determining clinical responsiveness to IFNβ therapy. This expert panel report attempts to move the field towards resolution of the remaining issues and considers several aspects of NAbs, including their clinical relevance, factors influencing immunogenicity, assays to quantify NAbs and the definition of clinically relevant titres.

Key words

neutralising antibodiesinterferon βmultiple sclerosisNAb+NAb-

Copyright information

© Steinkopff-Verlag 2007

Authors and Affiliations

  • H.-P. Hartung
    • 1
  • C. Polman
    • 2
  • A. Bertolotto
    • 3
  • F. Deisenhammer
    • 4
  • G. Giovannoni
    • 5
  • E. Havrdova
    • 6
  • B. Hemmer
    • 7
  • J. Hillert
    • 8
  • L. Kappos
    • 9
  • B. Kieseier
    • 1
  • J. Killestein
    • 2
  • C. Malcus
    • 10
  • M. Comabella
    • 11
  • A. Pachner
    • 12
  • H. Schellekens
    • 13
  • F. Sellebjerg
    • 14
  • K. Selmaj
    • 15
  • P. S. Sorensen
    • 14
  1. 1.Dept. of NeurologyHeinrich-Heine-UniversityDüsseldorfGermany
  2. 2.VU University Medical CenterAmsterdamThe Netherlands
  3. 3.A.S.O. San Luigi GonzagaRegione GonzoleTorinoItaly
  4. 4.Innsbruck Medical UniversityInnsbruckAustria
  5. 5.Institute of NeurologyLondonUnited Kingdom
  6. 6.Charles UniversityPragueCzech Republic
  7. 7.University of DüsseldorfDüsseldorfGermany
  8. 8.Karolinska University HospitalStockholmSweden
  9. 9.University Hospital BaselBaselSwitzerland
  10. 10.Hôpital Neurologique BronLyonFrance
  11. 11.Unitat de Neuroimmunologia ClinicaBarcelonaSpain
  12. 12.New Jersey Medical SchoolPrincetonUSA
  13. 13.Utrecht UniversityUtrechtThe Netherlands
  14. 14.Copenhagen University HospitalCopenhagenDenmark
  15. 15.Medical University of LódzLódzPoland